Overview

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This trial was conducted in Europe. The aim of this clinical trial was to evaluate if the NN1250 (insulin degludec/insulin 454) concentration-time curve is altered to such an extent that the dose should be adjusted in subjects with impaired renal function compared to the dose for subjects with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin
Insulin, Globin Zinc
Insulin, Long-Acting